» Articles » PMID: 31129110

A Retrospective Study of Comorbidities and Complications in Elderly Acute Myeloid Leukemia Patients in the United States

Overview
Publisher Elsevier
Specialty Oncology
Date 2019 May 27
PMID 31129110
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Comorbidities in acute myeloid leukemia (AML) patients have been shown to increase with age. However, few studies have described the disease burden in elderly AML patients, a population generally underrepresented in clinical trials. We aimed to characterize the comorbidities and complications in elderly AML patients.

Patients And Methods: Patients aged ≥ 65 years with a primary diagnosis of AML were identified from the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database (2000-2013) and were followed until the end of 2014. AML patients were matched 1:1 to noncancer patients by age, sex, geographic region, and race. A subset of patients with relapsed and/or refractory (R/R) AML was identified by modifying a previously validated algorithm. Baseline comorbidities and complications (eg, infectious, hematologic, cardiovascular) during follow-up were assessed using ICD-9 codes. Cox proportional hazards models were used to determine associations between AML and developing select complications.

Results: Compared to matched noncancer controls, AML patients (n = 3911) had higher baseline National Cancer Institute comorbidity index scores (1.81 vs. 1.63, P < .01), higher incidence rates (per 100 person-years) for all events of interest, and a higher risk of developing cardiovascular disease (hazard ratio = 4.61; 95% confidence interval, 4.07-5.21), type 2 diabetes mellitus (hazard ratio = 3.85; 95% confidence interval, 3.35-4.42), and stroke (hazard ratio = 2.60; 95% confidence interval, 2.32-2.92). R/R AML patients were younger, had lower National Cancer Institute comorbidity scores, lower incidence rates of events of interest, and a longer follow-up time compared to non-R/R AML patients.

Conclusion: Elderly AML patients had more comorbidities and higher rates of complications compared to noncancer controls. Considering comorbidities and complications in elderly AML patients may improve clinical decision making.

Citing Articles

Cardiovascular Considerations After Cancer Therapy: Gaps in Evidence and Expert Panel Recommendations.

Blaes A, Nohria A, Armenian S, Bergom C, Thavendiranathan P, Barac A JACC CardioOncol. 2025; 7(1):1-19.

PMID: 39896126 PMC: 11782100. DOI: 10.1016/j.jaccao.2024.06.006.


Venetoclax Combination Treatment of Acute Myeloid Leukemia in Adolescents and Young Adult Patients.

Chatzikalil E, Roka K, Diamantopoulos P, Rigatou E, Avgerinou G, Kattamis A J Clin Med. 2024; 13(7).

PMID: 38610812 PMC: 11012941. DOI: 10.3390/jcm13072046.


Low‑dose venetoclax combined with azacitidine in older and frail patients with newly diagnosed acute myeloid leukaemia.

Rong C, Yang F, Chen Y, Wang M, Ai C, Luo Y Oncol Lett. 2024; 27(5):228.

PMID: 38586209 PMC: 10996028. DOI: 10.3892/ol.2024.14362.


Ischemic Stroke as the Presenting Feature for Non-acute Promyelocytic Leukemia Variant of Acute Myeloid Leukemia: A Case Report.

Pankaj P, Panda C, Karim H, Bala S, Bidwaikar A Cureus. 2023; 15(6):e41083.

PMID: 37519500 PMC: 10377751. DOI: 10.7759/cureus.41083.


Amsacrine-based induction therapy in AML patients with cardiac comorbidities: a retrospective single-center analysis.

Kuron D, Pohlmann A, Angenendt L, Kessler T, Mesters R, Berdel W Ann Hematol. 2023; 102(4):755-760.

PMID: 36749402 PMC: 9998561. DOI: 10.1007/s00277-023-05111-x.